Publication: Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells
Submitted Date
Received Date
Accepted Date
Issued Date
2008-12-01
Copyright Date
Announcement No.
Application No.
Patent No.
Valid Date
Resource Type
Edition
Resource Version
Language
File Type
No. of Pages/File Size
ISBN
ISSN
1791244X
11073756
11073756
eISSN
Scopus ID
WOS ID
Pubmed ID
arXiv ID
Call No.
Other identifier(s)
2-s2.0-59149099449
Journal Title
Volume
Issue
item.page.oaire.edition
Start Page
End Page
Access Rights
Access Status
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Physical Location
Bibliographic Citation
International Journal of Molecular Medicine. Vol.22, No.5 (2008), 639-644
Citation
Ko Ichi Kawahara, Teruto Hashiguchi, Kiyoshi Kikuchi, Salunya Tancharoen, Naoki Miura, Takashi Ito, Yoko Oyama, Yuko Nawa, Kamal K. Biswas, Xiaojie Meng, Yoko Morimoto, Binita Shrestha, Hisayo Sameshima, Ikuro Maruyama (2008). Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/18814.
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells
Alternative Title(s)
Author's Affiliation
Author's E-mail
Editor(s)
Editor's Affiliation
Corresponding Author(s)
Creator(s)
Compiler
Advisor(s)
Illustrator(s)
Applicant(s)
Inventor(s)
Issuer
Assignee
Other Contributor(s)
Series
Has Part
Abstract
High mobility group box 1 (HMGB1) is a nonhistone nuclear protein which is released from the nucleus of activated macrophages into the extracellular space in response to stimuli such as endotoxin or necrosis. The HMGB1 functions as a potent proinflammatory cytokine in the extracellular spaces. Recently, HMGB1 has been implicated in the progression of atherosclerosis. However, the association between HMGB1 and the development of atherosclerosis is poorly understood. Therefore, we examined whether serotonin (5-HT), a key factor involved in the development of atherosclerosis, induced HMGB1 release in human umbilical vein endothelial cells (HUVECs). We found that 5-HT induced the release of HMGB1 but not of ERK1/2 and JNK from HUVECs via the 5-HT receptor (5-HT1B)/p38 mitogen-activated protein kinase (MAPK) signaling pathway. The p38MAPK inhibitor SB203580 and the 5-HT1B antagonist GR55526 markedly inhibited HMGB1 release from 5-HT-stimulated HUVECs. The vascular endothelial growth factor (VEGF) derived from activated macrophages in atherosclerotic lesions also plays an important role in the progression of atherosclerosis. We found that HMGB1 induced VEGF production in macrophage-like RAW264.7 cells. HMGB1 induced the activation of p38MAPK, ERK1/2 and Akt. The PI3-kinase inhibitor LY294002 significantly inhibited VEGF production in HMGB1-stimulated macrophages, while other kinase inhibitors did not. These results suggest that HMGB1 release may contribute as a risk factor in the development and progression of atherosclerosis.